NOVEL STEM CELL EXPANSION TECHNOLOGY
UNMODIFIED IMMUNE EFFECTOR CELL PROGRAM
Chimeric antigen receptor (CAR) therapy is a new treatment for cancer in which immune cells, either from the patient or from a donor, are genetically engineered to recognize cancer cells to target and destroy them. Currently approved CAR T therapies are revolutionizing the treatment of many blood cancers including B cell leukemias and lymphomas by targeting specific proteins found on these cancers, and there is hope in treating additional cancers including solid tumors by having them recognize new targets.
Coeptis is developing a novel approach to immune-based cell therapy called SNAP-CAR, where the CAR is connected to tumor cells via a SNAP molecule. Instead of directly binding to tumor cell, the CAR cells are co-administered with one or more antibody adaptors that bind to the tumor cells via a covalent bond. This type of bond is the highest affinity bond possible, thus this binding is expected to translate to highly potent therapeutic activity. The antibody adaptors can be increased (to heighten potency) or decreased (to reduce toxicity) as needed.
Pre-clinical studies in mice have demonstrated by targeting tumors via antibody adaptor molecules, the SNAP-CAR therapy provides a highly programmable therapeutic platform that may present several potential advantages over standard CAR T treatments. A number of different tumor targets have been successfully tested, with more testing ongoing.
Society for Immunotherapy of Cancer (SITC) 2023 Poster
Nature Communication (May 2023)
Animations herein are provided as visual aids to help articulate hypothesized proof-of-concept in a general manner and do not depict precise scientific mechanisms-of-action.
Corporate Headquarters 105 Bradford Road, Suite 420 Wexford, PA 15090 +1 (724) 934-6467 firstname.lastname@example.org
This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission. The statements that are not historical facts contained in releases or in our posted events and presentations are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company’s Securities and Exchange Commission filings. Coeptis Therapeutics Holdings, Inc. does not undertake any obligation to update forward-looking statements after the date of such releases except to the extent required under applicable federal and state securities laws. This website contains links to websites maintained by other companies. Coeptis Therapeutics is providing these links to readers only as a convenience. The inclusion of any link does not imply that Coeptis Therapeutics endorses any third-party website or third-party company or product. Coeptis Therapeutics does not have any control over the content of such third-party websites and assumes no responsibility whatsoever for the functionality of such websites or for the accuracy of any information presented at such other websites.
© Copyright Coeptis 2023